Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 391

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 391
---
 |     |             |      |     |           | — |
| Balance at June 30, 2025                                |     |             | 12,992 |   |     |           | 1.56 |     |             | 8.57 |     |           | — |
| Options vested and expected to vest as of June 30, 2025 |     |             | 12,992 |   |     |           | 1.56 |     |             | 8.57 |     |           |   |
| Options exercisable as of June 30, 2025                 |     |             |  3,415 |   |     |           | 1.73 |     |             | 6.99 |     |           |   |

F-52

LB Pharmaceuticals Inc Notes to Condensed Financial Statements (Unaudited) The weighted average grant date fair value of the stock options granted during the six months ended June 30, 2025 was $0.93. The Company granted 4.1 million stock options during the six months ended June 30, 2024 at a weighted average grant date fair value of $1.37. During the six months ended June 30, 2025 and 2024, the Company recognized stock-based compensation expense related to stock options as follows (in thousands):

|                                |     | Six Months Ended 
 June 30,         | 2025 |     |   | 2024 |
|:-------------------------------|:----|:-----------------|-----:|:----|:--|-----:|
| Research and development       |     | $                |  243 |     | $ |  154 |
| General and administrative     |     |                  |  724 |     |   |  185 |
| Total stock-based compensation |     | $                |  967 |     | $ |  339 |

As of June 30, 2025, there was $6.5 million unrecognized stock-based compensation expense which is expected to be recognized over a weighted average period of 3.40 years. No stock options were exercised or expired during the six months ended June 30, 2025 and 2024. There was less than 0.1 million stock options forfeited during the six months ended June 30, 2024. In connection with a reduction in force (“RIF”) initiated in May 2025, the Company modified stock